<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452696</url>
  </required_header>
  <id_info>
    <org_study_id>CALCIMIP18</org_study_id>
    <nct_id>NCT03452696</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Tolerability and Efficacy of Microencapsulated Calcium Carbonate</brief_title>
  <acronym>CALCIMIP</acronym>
  <official_title>Clinical Trial to Evaluate the Gastric Tolerability and Efficacy of the Food Supplement of Microencapsulated Calcium Carbonate vs Conventional Calcium Carbonate and Calcium Citrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nexentia S.A.S.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional Clinical trial with food supplement, randomized, double-blind, comparative
      between microencapsulated calcium, calcium carbonate salts standardized and calcium citrate,
      in a population of postmenopausal women, lasting 1 month.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Women</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric symptoms</measure>
    <time_frame>1 month</time_frame>
    <description>Using the Gastrointestinal Symptom Rating Scale (GRS). The scale measures constipation, diarrhea, windiness, swelling, nausea, reflux, pain and burning. The patient will have to choose the most appropriate response among those proposed. &quot;Not at all&quot; is the better outcome and &quot;very strong discomfort&quot; is the worst outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in bone markers</measure>
    <time_frame>Basal and 1 month</time_frame>
    <description>Bone Marker Analysis (CTx and P1NP) will be performed</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Hypocalcemia; Dietary</condition>
  <arm_group>
    <arm_group_label>Calcium supplement 10/90</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microencapsulated calcium, 1389 mg orally (10% protein and 90% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 doses of 1389 mg each orally, to make a total contribution of 1,000 mg. of calcium element.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium supplement 5/95</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microencapsulated calcium1316 mg orally (5% protein and 95% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 shots of 1,316 mg each orally, to make a total contribution of 1,000 mg. calcium element</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium carbonate supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1,250 mg orally (500 mg of calcium element). There will be 2 doses of 1,250 mg. each orally, to make a total contribution of 1,000 mg. of calcium element.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium citrate supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1,500 mg orally (315 mg of calcium element). There will be 2 taken orally, to make a total contribution of 945 mg. calcium element</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium supplement</intervention_name>
    <description>Calcium supplement for low contribution of elemental calcium in the daily diet</description>
    <arm_group_label>Calcium supplement 10/90</arm_group_label>
    <arm_group_label>Calcium supplement 5/95</arm_group_label>
    <arm_group_label>Calcium carbonate supplement</arm_group_label>
    <arm_group_label>Calcium citrate supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal woman

          -  Low contribution of elemental calcium in the daily diet

        Exclusion Criteria:

          -  Hypersensitivity to the active substances or to any of the excipients

          -  Renal insufficiency

          -  History of kidney or urinary stones

          -  Use in the last month of diuretics (furosemide, ethacrynic acid), aluminum salts and /
             or thyroid hormones

          -  Use of any other drug or experimental device during the 30 days prior to the selection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only women</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Palacios, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Palacios</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Santiago Palacios, MD</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>investigacion@institutopalacios.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Soler, SC</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>eva.maria.soler@institutopalacios.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Palacios</investigator_affiliation>
    <investigator_full_name>Dr. Santiago Palacios</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypocalcemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

